IL201834A0 - Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor - Google Patents

Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Info

Publication number
IL201834A0
IL201834A0 IL201834A IL20183409A IL201834A0 IL 201834 A0 IL201834 A0 IL 201834A0 IL 201834 A IL201834 A IL 201834A IL 20183409 A IL20183409 A IL 20183409A IL 201834 A0 IL201834 A0 IL 201834A0
Authority
IL
Israel
Prior art keywords
reversible
intravenous
inhibitor
acting
direct
Prior art date
Application number
IL201834A
Other languages
English (en)
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of IL201834A0 publication Critical patent/IL201834A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL201834A 2007-05-02 2009-10-29 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor IL201834A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US94792107P 2007-07-03 2007-07-03
PCT/US2008/062518 WO2008137753A2 (en) 2007-05-02 2008-05-02 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Publications (1)

Publication Number Publication Date
IL201834A0 true IL201834A0 (en) 2010-06-16

Family

ID=39587015

Family Applications (1)

Application Number Title Priority Date Filing Date
IL201834A IL201834A0 (en) 2007-05-02 2009-10-29 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Country Status (17)

Country Link
US (2) US20090048216A1 (OSRAM)
EP (1) EP2079464A2 (OSRAM)
JP (1) JP2010526101A (OSRAM)
KR (1) KR20100029746A (OSRAM)
CN (1) CN101795682A (OSRAM)
AU (1) AU2008247483A1 (OSRAM)
BR (1) BRPI0811476A2 (OSRAM)
CA (1) CA2686203A1 (OSRAM)
CO (1) CO6241104A2 (OSRAM)
EA (1) EA200901473A1 (OSRAM)
EC (1) ECSP099778A (OSRAM)
GT (1) GT200900284A (OSRAM)
IL (1) IL201834A0 (OSRAM)
MA (1) MA31663B1 (OSRAM)
MX (1) MX2009011843A (OSRAM)
TN (1) TN2009000451A1 (OSRAM)
WO (1) WO2008137753A2 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101423483B1 (ko) * 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
JP5390407B2 (ja) * 2007-03-06 2014-01-15 ノバルティス アーゲー 炎症またはアレルギー症状の処置に適する二環式有機化合物
JP2010526105A (ja) * 2007-05-02 2010-07-29 ポートラ ファーマシューティカルズ， インコーポレイテッド ［４−（６−フルオロ−７−メチルアミノ−２，４−ジオキソ−１，４−ジヒドロ−２ｈ−キナゾリン−３−イル）−フェニル］−５−クロロ−チオフェン−２−イル−スルホニルウレア塩、異なる結晶形態、その医薬組成物
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2384196B1 (en) * 2008-12-30 2017-09-13 Johansson, Pär Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8663661B2 (en) * 2009-12-23 2014-03-04 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor
WO2011088152A1 (en) 2010-01-12 2011-07-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
WO2012072743A1 (en) * 2010-12-01 2012-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and kits for determining platelet susceptibility to activation in a patient
JP2013544271A (ja) * 2010-12-03 2013-12-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 式（ｉ）の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法
BR112019014567A2 (pt) 2017-03-15 2020-02-18 Idorsia Pharmaceuticals Ltd Antagonista do receptor p2y12 ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de éster butílico do ácido
MA49452A (fr) 2017-06-23 2021-05-05 Chiesi Farm Spa Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
KR101423483B1 (ko) 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법

Also Published As

Publication number Publication date
WO2008137753A3 (en) 2009-02-12
EA200901473A1 (ru) 2010-06-30
JP2010526101A (ja) 2010-07-29
MX2009011843A (es) 2010-04-22
EP2079464A2 (en) 2009-07-22
US20120009172A1 (en) 2012-01-12
MA31663B1 (fr) 2010-09-01
GT200900284A (es) 2012-01-31
CN101795682A (zh) 2010-08-04
ECSP099778A (es) 2010-01-29
AU2008247483A1 (en) 2008-11-13
WO2008137753A2 (en) 2008-11-13
BRPI0811476A2 (pt) 2014-11-04
CA2686203A1 (en) 2008-11-13
US20090048216A1 (en) 2009-02-19
TN2009000451A1 (en) 2011-03-31
KR20100029746A (ko) 2010-03-17
CO6241104A2 (es) 2011-01-20

Similar Documents

Publication Publication Date Title
IL201834A0 (en) Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
IL219583A0 (en) Oral formulations of a hedgehog pathway inhibitor, methods of producing the same and uses thereof
TWI561183B (en) Oral care implement
SI2185198T1 (sl) Inhibitorji LOX in LOXL2 ter njihova uporaba
PT2807926T (pt) Sais e polimorfos de um composto de tetraciclina
EP2047820A4 (en) ORTHODONTIC FASTENING BRIDGE
IL212841A0 (en) Dpp iv inhibitor formulations
GB0625659D0 (en) Therapeutic compounds and their use
GB0703438D0 (en) Preventing spread of infection
PL2173345T3 (pl) Doustna formulacja metadoksyny
IL213694A0 (en) Melanin production inhibitor compounds and compositions comprising the same
GB0710439D0 (en) Oral dosage form
IL202765A0 (en) Pharmaceutical combination of nsaid and prostaglandin compound
ZA201103752B (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
EP2081606A4 (en) HYGIENE ARTICLE CONTAINING AN ANTI-MICROBIAL COMPOSITION
PL2271348T3 (pl) Doustny preparat związków tetracyklinowych w postaci tabletki
EP2195316A4 (en) ACTIVATORS AND THERAPEUTIC APPLICATIONS THEREOF
IL228484A0 (en) 2-mmp and/or 9-mmp inhibitors
PL2046268T3 (pl) Kompozycja do pielęgnacji jamy ustnej
EP2039362A4 (en) INHIBITOR OF THE DISSOLUTION OF DENTAL ENAMEL
HK1131567A (en) Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
GB2453072B (en) Oral care compositions
GB0622479D0 (en) Novel salts and their therapeutic use
GB0614538D0 (en) Therapeutic Compounds And Their Use
GB0810674D0 (en) Composition comprising a NSAID and paracetamol